THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A tablet comprising a first layer and a second layer wherein; a) the first layer comprises rilpivirine HCl, is substantially free of tenofovir disoproxil fumarate, and wherein less than about 12.2 weight percent of the first layer is rilpivirine HCl; b) the second layer comprises tenofovir disoproxil fumarate and is substantially free of rilpivirine HCl; and c) the tablet further comprises emtricitabine.

2. The tablet of claim 1 wherein the first layer does not comprise emtricitabine.

3. The tablet of claim 1 wherein the second layer comprises emtricitabine.

4. The tablet of any one of claims 1-3 which comprises 27.5 ± 1.4 mg of rilpivirine HCl.

5. The tablet of any one of claims 1-4 which comprises 200 ± 10.0 mg of emtricitabine.

6. The tablet of any one of claims 1-5 which comprises 300 ± 15.0 mg of tenofovir disoproxil fumarate.

7. The tablet of any one of claims 1-6 wherein the first layer further comprises one or more diluents, disintegrants, binders, or lubricants.

8. The tablet of any one of claims 1-3 and 5-7 wherein the total weight of the first layer is 275 ± 75 mg.

9. The tablet of any one of claims 1-3 and 5-7 wherein the total weight of the first layer is greater than 225 mg.

10. The tablet of any one of claims 1-3 and 5-8 wherein the total weight of the first layer is 275 ± 50 mg.

11. The tablet of any one of claims 1-10 wherein the first layer comprises a basifying agent.

12. The tablet of claim 11 wherein the basifying agent is selected from croscarmellose sodium, calcium carbonate, sodium hydroxide, aluminum oxide, alkali metal hydroxides, alkaline earth metal hydroxides, aluminum hydroxide, dihydroaluminum, sodium carbonate, ammonium hydroxides, magnesium carbonate, magnesium stearate, piperazine, sodium acetate, sodium citrate, sodium tartrate, sodium maleate, and sodium succinate and mixtures thereof.

13. The tablet of any one of claims 1-12 wherein the first layer comprises croscarmellose sodium, and polysorbate 20.

14. The tablet of any one of claims 1-12 wherein the first layer comprises lactose monohydrate, povidone, croscarmellose sodium, polysorbate 20, microcrystalline cellulose, and magnesium stearate.

15. The tablet of any one of claims 1-14 wherein the second layer comprises microcrystalline cellulose and croscarmellose sodium.

16. The tablet of any one of claims 1-14 wherein the second layer comprises lactose monohydrate, pre-gelatinized starch, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

17. The tablet of any one of claims 1-16 wherein the first layer is in contact with the second layer.

18. The tablet of any one of claims 1-16 that further comprises a third layer that is between and that separates the first layer and the second layer.

19. The tablet of claim 18 wherein the third layer comprises lactose monohydrate and/or microcrystalline cellulose.

20. The tablet of any one of claims 1-6 wherein the first layer is a polymeric film coating that is in contact with the second layer.

21. The tablet of claim 20 wherein the first layer is a polymeric film coating that completely covers the second layer.

22. The tablet of claim 3 wherein the first layer comprises:

Ingredient	**Unit Formula for Tablets (mg/tablet)**
Rilpivirine HCl	27.5 ± 1.4
Microcrystalline Cellulose	60.0 ± 3
Polysorbate 20	0.4 ± 0.02
Croscarmellose Sodium	16.1 ± 0.8

and the second layer comprises:

Ingredient	**Unit Formula for Tablets (mg/tablet)**
Emtricitabine	200 ± 10
Tenofovir disoproxil fumarate	300 ± 15
Microcrystalline Cellulose	150 ± 7.5
Croscarmellose Sodium	60 ± 3.

23. The tablet of claim 3 wherein the first layer consists of:

Ingredient	**Unit Formula for Tablets (mg/tablet)**
Rilpivirine HCl	27.5
Microcrystalline Cellulose	60.0
Lactose Monohydrate	189.8
Povidone	3.3
Polysorbate 20	0.4
Croscarmellose Sodium	16.1
Magnesium Stearate	3.0

and the second layer consists of:

Ingredient	**Unit Formula for Tablets (mg/tablet)**
Emtricitabine	200.0
Tenofovir disoproxil fumarate	300.0
Microcrystalline Cellulose	150.0
Lactose Monohydrate	80.0
Pregelatinized Starch	50.0
Croscarmellose Sodium	60.0
Magnesium Stearate	10.0.

24. The tablet of claim 18 wherein the first layer consists of:

Ingredient	Unit Formula for Tablets (mg/tablet)
Rilpivirine HCl	27.5
Microcrystalline Cellulose	60.0
Lactose Monohydrate	189.8
Povidone	3.3
Polysorbate 20	0.4
Croscarmellose Sodium	16.1
Magnesium Stearate	3.0

the second layer consists of:

Ingredient	Unit Formula for Tablets (mg/tablet)
Emtricitabine	200.0
Tenofovir disoproxil fumarate	300.0
Microcrystalline Cellulose	150.0
Lactose Monohydrate	80.0
Pregelatinized Starch	50.0
Croscarmellose Sodium	60.0
Magnesium Stearate	10.0

and the third layer comprises 150 ± 8.0 mg of microcrystalline cellulose or lactose monohydrate, or a mixture thereof.

25. The tablet of any one of claims 1-19 and 22-24 that further comprises a film coating.

26. The tablet of claim 25 wherein the film coating comprises 34 ± 12 mg of Opadry II Purple 33G100000.

27. A tablet having a first layer that consists of:

Ingredient	**mg**
Rilpivirine HCl	27.5
Microcrystalline Cellulose	60.0
Lactose Monohydrate	189.8
Povidone	3.3
Polysorbate 20	0.4
Croscarmellose Sodium	16.1
Magnesium Stearate	3.0
Total Layer Weight	300.0

a second layer that consists of:

Ingredient	**mg**
Emtricitabine	200.0
Tenofovir DF	300.0[b]
Microcrystalline Cellulose	150.0
Lactose Monohydrate	80.0
Pregelatinized Starch	50.0
Croscarmellose Sodium	60.0
Magnesium Stearate	10.0
Total Layer Weight	850.0

and a coating that consists of:

Ingredient	**mg**
Opadry II Purple 33G100000	34.5
Total Tablet Weight	1184.5.

28. The tablet of any one of claims 1-19 wherein at least about 5.4 weight percent of the first layer is croscarmellose sodium and at least about 63.3 weight percent of the first layer is lactose monohydrate.

29. The tablet of any one of claims 1-21 wherein less than about 12 weight percent of the first layer is rilpivirine hydrochloride.

30. The tablet of claim 1 wherein the first layer comprises 27.5 ± 1.4 mg of rilpivirine hydrochloride and wherein the total weight of the first layer is at least about 230 mg.

31. A tablet prepared as described herein, with the exception of the tablets of the Comparative Examples.

32. Use of a tablet as described in any one of claims 1-31 in the manufacture of a medicament for the prophylactic or therapeutic treatment of an HIV infection, wherein the medicament is formulated such that rilpivirine AUC achieved following administration to the human when fed is no more than about 25% greater than rilpivirine AUC achieved when administered to the human when fasted.

33. Use of a tablet as described in any one of claims 1-31 in the manufacture of a medicament for the prophylactic or therapeutic treatment of an HIV infection, wherein the medicament is formulated such that rilpivirine C_{max} achieved following administration to the human when fed is no more than about 25% greater than rilpivirine C_{max} achieved when administered to the human when fasted.

34. A tablet as described in any one of claims 1-31 for use in the prophylactic or therapeutic treatment of an HIV infection.

35. Use of a tablet as described in any one of claims 1-31 for preparing a medicament for treating HIV infection in a human.

36. A tablet comprising a first layer and a second layer wherein; a) the first layer comprises rilpivirine HCl and is substantially free of tenofovir disoproxil fumarate; b) the second layer comprises tenofovir disoproxil fumarate and is substantially free of rilpivirine HCl; and c) the tablet further comprises emtricitabine.

37. The tablet of claim 36 wherein the first layer does not comprise emtricitabine.

38. The tablet of claim 36 wherein the second layer comprises emtricitabine.

39. The tablet of any one of claims 36-38 which comprises 27.5 ± 1.4 mg of rilpivirine HCl.

40. The tablet of any one of claims 36-39 which comprises 200 ± 10.0 mg of emtricitabine.

41. The tablet of any one of claims 36-40 which comprises 300 ± 15.0 mg of tenofovir disoproxil fumarate.

42. The tablet of any one of claims 36-41 wherein the first layer further comprises one or more diluents, disintegrants, binders, or lubricants.

43. The tablet of any one of claims 36-42 wherein the total weight of the first layer is 275 ± 75 mg.

44. The tablet of any one of claims 36-43 wherein the total weight of the first layer is greater than 225 mg.

45. The tablet of any one of claims 36-44 wherein the total weight of the first layer is 275 ± 50 mg.

46. The tablet of any one of claims 36-45 wherein the first layer comprises a basifying agent.

47. The tablet of claim 46 wherein the basifying agent is selected from croscarmellose sodium, calcium carbonate, sodium hydroxide, aluminum oxide, alkali metal hydroxides, alkaline earth metal hydroxides, aluminum hydroxide, dihydroaluminum, sodium carbonate, ammonium hydroxides, magnesium carbonate, magnesium stearate, piperazine, sodium acetate, sodium citrate, sodium tartrate, sodium maleate, and sodium succinate and mixtures thereof.

48. The tablet of any one of claims 36-47 wherein the first layer comprises croscarmellose sodium, and polysorbate 20.

49. The tablet of any one of claims 36-47 wherein the first layer comprises lactose monohydrate, povidone, croscarmellose sodium, polysorbate 20, microcrystalline cellulose, and magnesium stearate.

50. The tablet of any one of claims 36-49 wherein the second layer comprises microcrystalline cellulose and croscarmellose sodium.

51. The tablet of any one of claims 36-49 wherein the second layer comprises lactose monohydrate, pre-gelatinized starch, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

52. The tablet of any one of claims 36-51 wherein the first layer is in contact with the second layer.

53. The tablet of any one of claims 36-51 that further comprises a third layer that is between and that separates the first layer and the second layer.

54. The tablet of claim 53 wherein the third layer comprises lactose monohydrate and/or microcrystalline cellulose.

55. The tablet of any one of claims 35-41 wherein the first layer is a polymeric film coating that is in contact with the second layer.

56. The tablet of claim 55 wherein the first layer is a polymeric film coating that completely covers the second layer.

57. The tablet of claim 38 wherein the first layer comprises:

Ingredient	**Unit Formula for Tablets (mg/tablet)**
Rilpivirine HCl	27.5 ± 1.4
Microcrystalline Cellulose	60.0 ± 3
Polysorbate 20	0.4 ± 0.02
Croscarmellose Sodium	16.1 ± 0.8

and the second layer comprises:

Ingredient	**Unit Formula for Tablets (mg/tablet)**
Emtricitabine	200 ± 10
Tenofovir disoproxil fumarate	300 ± 15
Microcrystalline Cellulose	150 ± 7.5
Croscarmellose Sodium	60 ± 3.

58. A tablet having a first layer that consists of:

Ingredient	**Unit Formula for Tablets (mg/tablet)**
Rilpivirine HCl	27.5
Microcrystalline Cellulose	60.0
Lactose Monohydrate	189.8
Povidone	3.3
Polysorbate 20	0.4
Croscarmellose Sodium	16.1
Magnesium Stearate	3.0

and a second layer that consists of:

Ingredient	Unit Formula for Tablets (mg/tablet)
Emtricitabine	200.0
Tenofovir disoproxil fumarate	300.0
Microcrystalline Cellulose	150.0
Lactose Monohydrate	80.0
Pregelatinized Starch	50.0
Croscarmellose Sodium	60.0
Magnesium Stearate	10.0.

59. The tablet of claim 53 wherein the first layer consists of:

Ingredient	Unit Formula for Tablets (mg/tablet)
Rilpivirine HCl	27.5
Microcrystalline Cellulose	60.0
Lactose Monohydrate	189.8
Povidone	3.3
Polysorbate 20	0.4
Croscarmellose Sodium	16.1
Magnesium Stearate	3.0

the second layer consists of:

Ingredient	Unit Formula for Tablets (mg/tablet)
Emtricitabine	200.0
Tenofovir disoproxil fumarate	300.0
Microcrystalline Cellulose	150.0
Lactose Monohydrate	80.0
Pregelatinized Starch	50.0
Croscarmellose Sodium	60.0
Magnesium Stearate	10.0

and the third layer comprises 150 ± 8.0 mg of microcrystalline cellulose or lactose monohydrate, or a mixture thereof.

60. The tablet of any one of claims 36-54 and 57-59 that further comprises a film coating.

61. The tablet of claim 60 wherein the film coating comprises Opadry II Purple 33G100000.

62. Use of a tablet as described in any one of claims 36-61 in the manufacture of a medicament for the prophylactic or therapeutic treatment of an HIV infection, wherein the medicament is formulated such that rilpivirine AUC achieved following administration to the human when fed is no more than about 25% greater than rilpivirine AUC achieved when administered to the human when fasted.

63. Use of a tablet as described in any one of claims 36-61 in the manufacture of a medicament for the prophylactic or therapeutic treatment of an HIV infection, wherein the medicament is formulated such that rilpivirine C_{max} achieved following administration to

the human when fed is no more than about 25% greater than rilpivirine C_{max} achieved when administered to the human when fasted.

64. A tablet as described in any one of claims 36-61 for use in the therapeutic treatment of an HIV infection.

65. The use of a tablet as described in any one of claims 36-61 for preparing a medicament for treating HIV infection in a human.